West Pharmaceutical Services Inc Revenue Growth Rates (WST), Current and Historic Growth - CSIMarket
CSIMarket
 


West Pharmaceutical Services Inc   (NYSE: WST)
 

WST's Revenue Growth by Quarter and Year

West Pharmaceutical Services Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/WST/growth
https://api.csimarket.com/api/v1/companies/WST/fundamentals
https://api.csimarket.com/api/v1/companies/WST/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
WST Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 874.50
2nd Quarter June 872.30
1st Quarter March 844.40
FY 2,591.20

WSTs Annual Revenue
West Pharmaceutical Services Inc 's Revenue in the fiscal year 2025 $ 3,074.00 millions
West Pharmaceutical Services Inc 's Revenue in the fiscal year 2024 $ 2,892.50 millions
West Pharmaceutical Services Inc 's Revenue in the fiscal year 2023 $ 2,949.20 millions
West Pharmaceutical Services Inc 's Revenue in the fiscal year 2022 $ 2,886.90 millions
West Pharmaceutical Services Inc 's Revenue in the fiscal year 2021 $ 2,831.60 millions




WST Revenue third quarter 2026 Y/Y Growth Comment
West Pharmaceutical Services Inc achieved in the third quarter 2026, above Company average Revenue improvement of 8.73% year on year, to $ 874.50 millions.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 77 other companies have achieved higher Revenue growth. While West Pharmaceutical Services Inc ' s Revenue increase of 8.73% ranks overall at the positon no. 1405 in the third quarter 2026.




WST Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 8.73 %
2nd Quarter June 13.89 %
1st Quarter March 20.99 %
FY   -

Financial Statements
West Pharmaceutical Services Inc 's third quarter 2026 Revenue $ 874.50 millions WST's Income Statement
West Pharmaceutical Services Inc 's third quarter 2025 Revenue $ 804.30 millions Quarterly WST's Income Statement


WST Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.25 %
2nd Quarter June 3.3 %
1st Quarter March 4.78 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #78
Healthcare Sector #245
Overall #1405

Revenue Y/Y Growth Statistics
High Average Low
37.25 % 5.96 % -100 %
(Dec 31 2021)  
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #78
Healthcare Sector #245
Overall #1405
Revenue Y/Y Growth Statistics
High Average Low
37.25 % 5.96 % -100 %
(Dec 31 2021)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

West Pharmaceutical Services Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
15.6 % 0.24 % -100 %
(Mar 31 2021)  


WST's III. Quarter Q/Q Revenue Comment
West Pharmaceutical Services Inc achieved in the III. Quarter 2026 above company average sequential Revenue growth of 0.25%, to $ 874.50 millions, from $872.30 millions in the second quarter.

Within Medical Equipment & Supplies industry 47 other companies have achieved higher Revenue quarter on quarter growth. While West Pharmaceutical Services Inc 's Revenue growth quarter on quarter, overall rank is 1250.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #48
Healthcare Sector #175
Overall #1250
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #48
Healthcare Sector #175
Overall #1250
Revenue Q/Q Growth Statistics
High Average Low
15.6 % 0.24 % -100 %
(Mar 31 2021)  


WST's III. Quarter Q/Q Revenue Comment
West Pharmaceutical Services Inc achieved in the III. Quarter 2026 above company average sequential Revenue growth of 0.25%, to $ 874.50 millions, from $872.30 millions in the second quarter.

Within Medical Equipment & Supplies industry 47 other companies have achieved higher Revenue quarter on quarter growth. While West Pharmaceutical Services Inc 's Revenue growth quarter on quarter, overall rank is 1250.


West Pharmaceutical Services Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)
12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 3,397.10
Y / Y Revenue Growth (TTM) 12.61 %
Year on Year Revenue Growth Overall Ranking # 2176
Seqeuential Revenue Change (TTM) 2.11 %
Seq. Revenue Growth (TTM) Overall Ranking # 2242


Cumulative Revenue growth Comment
West Pharmaceutical Services Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 12.61% year on year, to $ 3,397 millions if the fiscal year would have ended in Sep 30 2026.
West Pharmaceutical Services Inc 's trailing twelve months Revenue growth was higher than company's average 7.49% and higher than 12.43% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 2.11 % from $3326.9 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at7.49%.

In the Healthcare sector 314 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1774 to 2176.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 121
Healthcare Sector # 315
Overall # 2176

Revenue TTM Y/Y Growth Statistics
High Average Low
31.89 %
7.49 %
-4.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 325
S&P 500 # 2242
Cumulative Revenue growth Comment
West Pharmaceutical Services Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 12.61% year on year, to $ 3,397 millions if the fiscal year would have ended in Sep 30 2026.
West Pharmaceutical Services Inc 's trailing twelve months Revenue growth was higher than company's average 7.49% and higher than 12.43% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 2.11 % from $3326.9 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at7.49%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 2.11 % increase from $3326.9 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 314 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1774 to 2176.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 121
Healthcare Sector # 315
Overall # 2176

Revenue TTM Y/Y Growth Statistics
High Average Low
31.89 %
7.49 %
-4.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 325
S&P 500 # 2242




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
WST's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions
Royalty Pharma Plc13.26%$ 13.263 millions
Evolus Inc 13.23%$ 13.235 millions
Privia Health Group Inc 13.19%$ 13.187 millions
Biocryst Pharmaceuticals Inc 13.11%$ 13.110 millions
U S Physical Therapy Inc12.90%$ 12.898 millions
Maravai Lifesciences Holdings Inc 12.78%$ 12.781 millions
Alphatec Holdings Inc 12.67%$ 12.670 millions
Harmony Biosciences Holdings inc 12.61%$ 12.609 millions
Medicinova Inc 12.35%$ 12.355 millions
Bionano Genomics Inc 12.34%$ 12.339 millions
Viemed Healthcare Inc 12.18%$ 12.180 millions
Ufp Technologies Inc 12.15%$ 12.154 millions
Innovage Holding Corp 12.14%$ 12.135 millions
Vertex Pharmaceuticals Inc11.85%$ 11.845 millions
Sanara Medtech Inc 11.67%$ 11.668 millions
Lemaitre Vascular Inc 11.51%$ 11.508 millions


About West Pharmaceutical Services Inc Revenue Growth Rates (WST), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: West Pharmaceutical Services Inc (CIK 105770).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000105770-26-000121
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: West Pharmaceutical Services Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.